{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Hepion Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"HEPA"},"Address":{"label":"Address","value":"399 THORNALL STREET,1ST FLOOR, EDISON, New Jersey, 08837, United States"},"Phone":{"label":"Phone","value":"+1 732 902-4000"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.hepionpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Daren Ure","title":"Chief Scientific Officer"},{"name":"John Patrick Brancaccio","title":"Chairman, Chief Executive & Financial Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}